Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

समान संसाधन

• Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
  द्वारा: Wester, Ruth, और अन्य
  प्रकाशित: (2019)
• Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
  द्वारा: Sonneveld, Pieter, और अन्य
  प्रकाशित: (2015)
• Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
  द्वारा: Lokhorst, Henk M., और अन्य
  प्रकाशित: (2015)
• Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
  द्वारा: Wester, Ruth, और अन्य
  प्रकाशित: (2020)
• Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
  द्वारा: Franssen, Laurens E., और अन्य
  प्रकाशित: (2018)